Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP51A1 | Q16850 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21009583 | 1.00 | LMNA (0.57) | LMNASMN1; SMN2L3MBTL1GAACFTR | |
| SCHEMBL32346286 | 1.00 | LMNA (0.57) | LMNASMN1; SMN2L3MBTL1GAACFTR | |
| SCHEMBL1579049 | 1.00 | LMNA (0.57) | LMNASMN1; SMN2L3MBTL1GAACFTR | |
| Hydrochloric Acid SCHEMBL5448253 | 0.98 | LMNA (0.55) | LMNASMN1; SMN2L3MBTL1GAACFTR | |
| SCHEMBL9830214 | 0.85 | SMN1; SMN2 (0.53) | LMNASMN1; SMN2L3MBTL1GAACFTR | |
| SCHEMBL906187 | 0.85 | SMN1; SMN2 (0.53) | LMNASMN1; SMN2L3MBTL1GAACFTR | |
| SCHEMBL18557391 | 0.84 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2L3MBTL1GAACFTR | |
| SCHEMBL9629718 | 0.83 | L3MBTL1 (0.51) | LMNASMN1; SMN2L3MBTL1GAACFTR | |
| SCHEMBL2012891 | 0.82 | L3MBTL1 (0.50) | LMNASMN1; SMN2L3MBTL1GAACFTR | |
| SCHEMBL25233552 | 0.82 | SMN1; SMN2 (0.57) | LMNASMN1; SMN2L3MBTL1GAACFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4646414-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646416-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| WO-2024148091-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148087-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| US-11932648-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230322791-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-10-12 | — | — | US | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| EP-1123405-A1 | MATERIALS AND METHODS INVOLVING CONDITIONAL AGGREGATION DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023600-A1 | MATERIALS AND METHODS INVOLVING CONDITIONAL AGGREGATION DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932648-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | LMNA 2403/4885SMN1; SMN2 2189/4885L3MBTL1 2771/4885 |
| US-20230322791-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | LMNA 2403/4885SMN1; SMN2 2189/4885L3MBTL1 2771/4885 |
| US-11970498-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | LMNA 2403/4885SMN1; SMN2 2189/4885L3MBTL1 2771/4885 |
| US-20240383902-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | LMNA 2403/4885SMN1; SMN2 2189/4885L3MBTL1 2771/4885 |
| US-20230159535-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | LMNA 2403/4885SMN1; SMN2 2189/4885L3MBTL1 2771/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | LMNA 1435/4885SMN1; SMN2 2767/4885L3MBTL1 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.